UCB Consensus

Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of almost 20 different brokers. See the list of analysts and their contact details here.

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.

ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million	2020a	2021e	2022e	2023e	2024e	2025e	2026e	Peak Sales	NPV
Core Products
Cimzia	1,799	1,877	1,958	1,976	1,828	1,540	1,340		5,153
Vimpat	1,451	1,542	1,125	747	599	515	422		2,209
Keppra	788	754	682	623	575	534	484		2,236
Briviact	288	352	424	488	544	585	572	632	1,909
Neupro	311	276	235	205	178	155	146		573
Potential new Product Launches (global sales, non-risk adj.)
Evenity (romosozumab)		518	682	825	954	1,055	1,174	1,329	2,186
Nayzilam	26	50	73	96	117	129	134	165	376
Bimekizumab		97	360	708	1,095	1,494	1,744	2,554	6,184
Zilucoplan		0	11	133	303	497	683	1,162	2,202
Rozanolixizumab		0	11	81	199	355	468	928	1,700
Dapimab		7	16	34	57	110	120
Staccato alprazolam		0	0	2	23	74	86	270	395
UCB0107 (Anti-Tau)		0	0	0	37	92	148

UCB FY Consensus Earnings Estimates (Average)

In € million	2020a	2021e	2022e	2023e	2024e	2025e
Net Sales	5,052	5,339	5,264	5,325	5,604	5,801
Revenue	5,347	5,576	5,495	5,548	5,820	6,026
Adjusted EBIT	1,093	1,206	1,251	1,312	1,492	1,611
Adjusted EBITDA	1,441	1,561	1,602	1,676	1,864	1,984
Net Profit*	732	911	948	1,015	1,173	1,296
Core EPS (€)	5.36	5.74	5.89	6.33	7.16	7.79

_{*attributable to UCB shareholders}

UCB FY Consensus Product Sales Estimates (Median)

In € million	2020a	2021e	2022e	2023e	2024e	2025e	2026e	Peak Sales	NPV
Core Products
Cimzia	1,799	1,890	1,996	1,965	1,832	1,522	1,327		4,971
Vimpat	1,451	1,532	1,061	647	561	495	421		2,406
Keppra	788	744	680	625	580	535	475		1,992
Briviact	288	346	421	485	542	590	565	626	1,684
Neupro	311	280	238	198	166	146	144		537
Potential new Product Launches (global sales, non-risk adj.)
Evenity (romosozumab)		504	682	824	947	1,038	1,145	1,281	1,975
Nayzilam	26	48	70	90	116	130	134	150	409
Bimekizumab		78	340	700	1,048	1,443	1,747	2,618	5,923
Zilucoplan		0	0	140	302	463	591	1,137	2,069
Rozanolixizumab (Rozimab)		0	0	75	175	344	492	925	1,578
Dapimab		0	0	0	0	50	113
Staccato alprazolam		0	0	0	23	65	82	200	420
UCB0107 (Anti-Tau)		0	0	0	3	53	45

UCB FY Consensus Earnings Estimates (Median)

In € million	2020a	2021e	2022e	2023e	2024e	2025e
Net Sales	5,052	5,324	5,202	5,320	5,667	5,790
Revenue	5,347	5,578	5,416	5,520	5,888	6,000
Adjusted EBIT	1,093	1,194	1,254	1,334	1,467	1,638
Adjusted EBITDA	1,441	1,550	1,646	1,684	1,857	2,027
Net Profit*	732	908	951	986	1,155	1,307
Core EPS (€)	5.36	5.72	5.93	6.38	7.08	7.97

*attributable to UCB shareholders

Downloads:
UCB HY 2020 & FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated 15 March 2021

Check out UCB's new IR Apps:

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.